

# Saccharomyces™



## CLINICAL APPLICATIONS

- Current Antibiotic Rx
- Diarrhea-predominant IBS/ Fargile Digestive Tract
- C- difficile Toxin
- Acute or Chronic Gastroenteritis
- Colitis, including Pseudo-membranous
- Acute Diarrhea in Infants

*360 Medicine® in collaboration with renowned microbiology company Institut Rosell, is the first verified strain of Saccharomyces boulardii (SB), Saccharomyces™. The strain of SB in Saccharomyces™ has been researched extensively in American and European Universities and has been published in many peer-reviewed, and major scientific journals. Saccharomyces™ has been shown to promote overall intestinal health.*

*Saccharomyces™ is manufactured in a Federal Drug Registered and State Board Pharmacy cGMP laboratory*

## DISCUSSION

Saccharomyces™ is manufactured by Institut Rosell®, who employs a proprietary production process that does not require lactose to be in the formula. Saccharomyces™ is perfect for patients who are dairy/ lactose intolerant and safe for infants through elderly. However, as a precaution, it is not recommended to give probiotics to severely immuno-depressed patients, people who have recently had cardiac, oral or gastrointestinal surgery, patients presenting with pancreatic dysfunction or bloody diarrhea, patients under radiation therapy, or infants with short bowel syndrome.

Saccharomyces Boulardii has the following three mechanisms of action: 1.) Serves as an anti-toxin against bacterial toxins. 2) Stimulates immune cells of the intestinal mucosa. 3) Modulates the release of polyamines that repair intestinal health.

The large surface area of this special yeast's mannose-dominant outer membrane allows it to bind bacteria such as E. coli and Salmonella ssp., preventing the bacteria from adhering to the intestinal epithelium and possibly expelling these pathogens from the body via the stool.

Clostridium difficile-infected mice given Sb were protected from the infection. Castex and his colleagues explained that the yeast inactivated the Clostridium toxin. In another similar experiment Qamar demonstrated a fourfold increase in specific IgA in mice administered C difficile toxin A after pre-treatment with Sb.

In a placebo-controlled study on the use of Sb to prevent Antibiotic Associated Diarrhea, (AAD) the percentage of pts who experienced the problem in the placebo group compared to the Sb-treated group was 21.8% compared to only 9.5%. Another study by Marteau showed that the Sb treatment cut the risk of AAD in half.

Saccharomyces has been extensively researched and published in European and American peer-reviewed journals. (Please see references for studies cited, as well as a portion of those in the literature)

Other Ingredients: HPMC, Potato Starch, Magnesium Stearate.

HPMC is hydroxypropylmethylcellulose, the highly purified, hypo-allergic, non-GMO form of cellulose that is physiologically inert. It is what constitutes the capsule.



## Supplement Facts

Serving Size: 1 Capsule  
Servings Per Container: 60

	Amount Per Serving	%Daily Value
Saccharomyces boulardii lyo (5 billion live organism per capsules)	250 mg	**

\*\* Daily Value not established.

**Other Ingredients:** HPMC, Potato Starch, and Magnesium Stearate.

## DOSING

The general recommendation is one capsule twice a day or as directed by the health care practitioner. The dose is the same regardless of age. Saccharomyces™ may be taken at the same time as an antibiotic.

## REFERENCES

1. Cothier GF, Lucas F, Jouvest S, Castex F. Effects of *S. boulardii* treatment on the activity of C-difficile toxins in mouse digestive tract. *Toxicon*. 1992; 30:1583-1589.
2. Qamar A, Abioudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP. *Saccharomyces boulardii* stimulates intestinal Immunoglobulin A immune response to *Colstridium difficile* toxin A in mice. *Infection and Immunity* 2001; 69:2762-65.
3. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, Harrington G, Rubin M, Greenwald D. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standrad antibiotics for *Clostridium difficile* disease. *Journal of the American Medical Association* 1994; 271:1913-18.
4. Marteau P, Scksik P, Jian R. Probiotics and intestinal health effects: a clinical perspective. *Br J Nutr* 2002; 1:S 51-7.
5. Buts JP, Bernasconi P, Vaerman JP, Dive C Response of human and rat small intestinal mucosa to oral administration of *Saccaromyces boulardii*. *Pediatric Research* 1986; 20: 192-96.
6. Buts JP, De Keyser N, De Raedemaeker L. *Saccharomyces boulardii* enhances rat intestinal enzyme expression by endoluminal release of polyamines. *Pediatric Research* 1994; 36:522-27.
7. Zaouche A, Loukil C, de Lagausie P, Peuchmaur M, Macry J, Fitoussi F, Bernasconi P, Bingen E, Cezard JP Effects of oral *Saccharomyces boulardii* on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in rats. *Scandinavian Journal of Gastroenterology* 2000;35: 160-65.
8. Buts JP, Corthier G, Delmee, M. *Saccharomyces boulardii* for *Colstridium difficile*-associated enteropathies in infants. *Journal of Pediatric Gastroenterolgy and Nutrition* 1993; 16: 419-25.
9. Castagliulo 1, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. *Saccharomyces boulardii* protease mediates *Clostridium difficile* toxin A and B effects in human clonic mucosa. *Infection and Immunity* 1999; 67: 302-07.
10. Castex F, Corthier G, Joubert S, Elmer GW, Lucas F, Bastide M. Prevention of *Clostridium difficile*-induced experimental pseudomembranous colitis by *Saccharomyces boulardii*: a scanning electron microscopic and microbiological study. *Journal of General Microbiology* 1990; 136: 1085-89.
11. Gaon D, Garcia H, Winter L, Rodriguez N, Quintas R, Gonzalez SN, Oliver G. Effect *Lactobacillus* strains and *Saccharomyces boulardii* on persistent diarrhea in children. *Medicina (B Aires)*. 2003;63(4): 293-8. [PMID: 14518142]
12. Elmer GW, McFarland LV, Surawicz CM, Dankos L, Greenburg RN, Behavior of *Saccharomyces boulardii* in recurrent *Clostridium difficile* disease patients. *Alimentary Pharmacology and Therapeutics* 1999;13: 1663-68.
13. Reid G. et al. New scientific paradigms for probiotics and prebiotics. *J Clin Gastr*. 2003; 37(2):105-118. [PMID:12869879]
14. Bergogne-Berezin E. Treatment and prevention of antibiotics associated diarrhea. *International Journal of Microbiolial Agents* 16 2000; 521-26.
15. Van der Aa Kuhle A, Jespersen L. The taxonomic position of *Saccharomyces boulardii* is evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochrome-c oxidase II gene. Department of Dairy and Food Science, Food Microbiology, The royal Veterinary and Agricultural University, Copenhagen, Denmark.

Additional references available upon request .

## STORAGE

Do not refrigerate. Keep tightly covered in cool, dry place.

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

